ArticleTranslational cancer research2026
Predicting the prognosis of small intestinal stromal tumors in the post-imatinib era: a study based on the SEER database.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis of small intestinal stromal tumors (SISTs) in the post-imatinib era is influenced by a complex interplay of clinicopathological factors. This study aimed to develop and validate predictive models for overall survival (OS) and cancer-specific survival (CSS) in patients with SISTs using data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods: We retrospectively analyzed 3,504 patients diagnosed with SISTs between 2012 and 2023. Patients were randomly divided into a training cohort (n=2,453) and a testing cohort (n=1,051). Cox proportional hazards regression analyses were performed in the training cohort to identify independent prognostic factors for OS and CSS. Significant predictors were used to construct nomograms for predicting 1-, 3-, and 5-year survival probabilities. The models' performance was evaluated using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA) in both the training and testing cohorts. Results: Multivariate Cox regression analysis identified age ≥65 years, male sex, high tumor grade (III/IV), distant metastasis (M1), no surgery, unmarried status, and no chemotherapy as independent risk factors for worse OS (all P<0.01). For CSS, independent risk factors included age ≥65 years, high tumor grade (III/IV), lymph node metastasis (N1), distant metastasis (M1), and no surgery (all P<0.05). These factors were incorporated into the nomograms, which demonstrated satisfactory predictive accuracy. In the testing cohort, the area under the curve (AUC) for the OS nomogram at 1, 3, and 5 years were 0.763, 0.728, and 0.758, and for the CSS nomogram were 0.763, 0.784, and 0.801. Calibration curves showed good agreement between predicted and observed survival, and DCA confirmed the clinical utility of the nomograms. Conclusions: We developed and validated promising nomograms for predicting OS and CSS in patients with SISTs. These models, incorporating readily available clinicopathological factors, may serve as a supplementary tool for individualized risk stratification and clinical decision-making in the post-imatinib era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.